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Abstract
Malignant mesothelioma (MMe) is a highly aggressive, lethal tumour requiring the development of more effective therapies. The green tea
polyphenol epigallocathechin-3-gallate (EGCG) inhibits the growth of many types of cancer cells. We found that EGCG is selectively cytotoxic to
MMe cells with respect to normal mesothelial cells. MMe cell viability was inhibited by predominant induction of apoptosis at lower doses and
necrosis at higher doses. EGCG elicited H2O2 release in cell cultures, and exogenous catalase (CAT) abrogated EGCG-induced cytotoxicity,
apoptosis and necrosis. Confocal imaging of fluo 3-loaded, EGCG-exposed MMe cells showed significant [Ca2+]i rise, prevented by CAT,
dithiothreitol or the T-type Ca2+ channel blockers mibefradil and NiCl2. Cell loading with dihydrorhodamine 123 revealed EGCG-induced ROS
production, prevented by CAT, mibefradil or the Ca2+ chelator BAPTA-AM. Direct exposure of cells to H2O2 produced similar effects on Ca
2+ and
ROS, and these effects were prevented by the same inhibitors. Sensitivity of REN cells to EGCG was correlated with higher expression of Cav3.2
T-type Ca2+ channels in these cells, compared to normal mesothelium. Also, Cav3.2 siRNA on MMe cells reduced in vitro EGCG cytotoxicity and
abated apoptosis and necrosis. Intriguingly, Cav3.2 expression was observed in malignant pleural mesothelioma biopsies from patients, but not
in normal pleura. In conclusion, data showed the expression of T-type Ca2+ channels in MMe tissue and their role in EGCG selective cytotoxicity
to MMe cells, suggesting the possible use of these channels as a novel MMe pharmacological target.
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Introduction
Malignant mesothelioma (MMe) is a highly aggressive tumour arising
from mesothelial cells of the serosal surfaces of body cavities, mainly
the pleura. The incidence of this tumour is increasing worldwide
because of exposure to asbestos, while the prognosis for patients
is still poor, with a median survival of about 12 months [1].
Chemotherapy is the most widely used clinical approach, with various
cytotoxic drugs having already been tested [2–4]. The response rate
is higher for drug combinations than for single-agent regimens, but
no satisfactory therapy has yet been defined, therefore, the develop-
ment of novel translational therapies is urgent [5, 6].
In the light of current failures in MMe therapies, we have
addressed the possibility of combining anti-cancer active nutrients
with chemotherapy drugs, to obtain synergistic treatments along
with reduced side effects [7]. We have previously shown that
ascorbate, which is known to produce H2O2 [8], exerts anti-tumour
properties on mesothelioma through a stronger oxidative stress in
MMe cells compared to normal mesothelial cells [9]. It is well
established that different chemotherapeutic agents generate reactive
oxygen species (ROS) in patients during cancer therapy [10].
Thereafter, oxidative stress induces a series of cell responses
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depending on the genetic background, the types of ROS involved
and the intensity and duration of the stimulus. Such a complex of
factors will determine whether a cell will survive or undergo
necrosis or apoptosis.
Epigallocathechin-3-gallate (EGCG) is a flavan-3-ol polyphenol
produced by green tea, which is known to exert anti-tumour activity
in many types of cancer cells [11–16]. In several cases, transformed
cells have been found to be more sensitive to EGCG than their normal
counterparts [17]. Following this body of evidence, EGCG has been
proposed as a possible chemopreventive or chemotherapeutic agent
in the treatment of cancer [18–20]. In a vast array of studies, it has
been shown that EGCG can modify the physiology of cells by
interacting with a large set of protein targets [21]. Accordingly, a
number of mechanisms have been put forward to explain the anti-
tumour activity of EGCG, including, among others, induction of cell
cycle arrest [22], inhibition of factors like NF-jB [12], insulin-like
growth factor I receptor [23], c-Met receptor [24], matrix metallopro-
teinase [25, 26] and proteasome [27], suppression of Wnt signalling
[28], of the expression of HSP70 and HSP90 [29] and of the tumour-
promoter TROP2 [30], down-regulation of the EGF receptor [31],
activation of TNF-a-mediated signalling [32] and induction of
p53-dependent [20] and ASK1-p38/JNK-dependent apoptosis [33].
Even though gallocatechins are generally known to be strong
antioxidants [34], there is evidence that some of the effects of these
compounds may be related to ROS release. Transition metals, primar-
ily Cu and Fe, are capable of initiating phenolic oxidations and are
essential catalysts in this process. These reactions yield superoxide
(O2
–•) or its protonated hydroperoxyl radical (HO2
•), which can be fur-
ther reduced to hydrogen peroxide [35]. In line with these findings, it
has been shown that EGCG can also inhibit cancer cell growth
through pro-oxidant activities [36–38], and also in this respect,
normal cells have been reported to be less sensitive than tumours to
the action of EGCG [39]. Data also suggest that pro-oxidant effects
may play a role in the anti-tumour or toxic effects of EGCG that have
been observed in vivo on animal models [40].
In this study, we have described the in vitro selective oxidative
toxicity to MMe cells of EGCG, which, as previously shown, has been
found to generate H2O2 in the cell medium [41]. Moreover, we have
provided the first demonstration of T-type Ca2+ channels expression
in MMe cells and concomitantly, have defined a novel mechanism of
action for EGCG. This mechanism involves the induction of T-channel
opening by H2O2, followed by [Ca
2+]i homeostasis impairment, induc-
tion of intracellular ROS and eventually cell apoptosis or necrosis,
depending on the intensity of the stimulus. These findings suggest
the possible use of EGCG for MMe, and indicate T-type Ca2+ channels
as a novel therapeutic target.
Materials and methods
Reagents
Reagents were purchased from Sigma-Aldrich (Milan, Italy), unless
otherwise indicated.
Cell culture
In vitro experiments were carried out on both mesothelioma and normal
mesothelial cell lines. The following human MMe cells were used: REN
is a tumourigenic, p53-mutant, epithelial subtype [42]; MM98 were
established from pleural effusion of a sarcomatous MMe [43]; BR95
and E198 were obtained from pleural effusions of MMe patients with
histologically confirmed MMe and confirmed by immunostaining [44];
MPP89 are epithelial-like MMe cells [43]; primary mesothelial cells,
were obtained from the inner surface of surgically removed hernial sacs
[9]. HMC-hTERT are mesothelial cells obtained from patients with con-
gestive heart failure and immortalized by expression of the hTERT
human telomerase subunit [45]. Cells were cultured in DMEM supple-
mented with 10% foetal bovine serum (FBS; Euroclone, Pero, Italy) and
1% antibiotic mixture (Gibco, Invitrogen Life Technologies, S. Giuliano
Milanese, Italy).
Cell viability assays
The calcein assay was carried out using the lipophilic, nonfluorescent
calcein-acetoxymethylester (calcein-AM), which penetrates cell
membranes and is then cleaved by intracellular esterases, yielding the
hydrophilic fluorescent dye. Cells growing in 96-well plates were treated
with EGCG as specified, washed with PBS, and then incubated for
30 min. at 37°C with a solution of 2.5 lM calcein-AM in PBS. Plates
were read in a fluorescence reader (Infinite 200 Pro, Tecan), by using
485-nm exc and 535-nm em filters.
Cell viability was also evaluated through DNA-based cell counting,
using the Hoechst 33258 DNA dye (bisbenzimide; p-(5-(5-(4-methyl-1-
piperazinyl)-1H-2-benzimidazolyl)-1H-2-benzimidazolyl) phenol trihydro-
chloride). Cells growing in 96-well plates were treated with EGCG as
specified, and then washed in PBS and permeabilized with 100 ll of
10 M urea and 0.01% SDS for 30 min. at 37°C. Thereafter, 100 ll of
1 lg/ml Hoechst solution in PBS were added to wells, plates were
incubated for 30 min. at 37°C, and read in the plate reader, using
355-nm exc and 460-nm em filters.
In both DNA and calcein fluorimetric assays, the degree of fluores-
cence was converted to cell number by using calibration standard
curves obtained from wells containing numbers of cells ranging from 5
to 40 9 103, as determined using a haemocytometer.
H2O2 and protein assays
The formation of H2O2 induced by EGCG in tissue culture medium was
determined by the Colorimetric Hydrogen Peroxide kit (Assay Designs,
Ann Arbor, MI, USA) as described in Ranzato et al. [9].
Total protein in cell lysates was determined using the bicinchoninic
acid-based BCA Protein Assay Kit (Pierce, Rockford, IL, USA), following
the manufacturer’s protocol. Microplates were read at 540 nm using a
plate reader (Sirio S, SEAC, Florence, Italy).
LDH and caspase 3 assays
The rate of cell necrosis induced by EGCG was detected using the
lactate dehydrogenase (LDH) assay. The analysis was performed on cell
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supernatants according to the method of Legrand et al. [46], by using
the Cytotoxicity Detection Kit (Roche Diagnostics GmbH, Mannheim,
Germany). Absorbances were read at 492 nm using the Infinite 200 Pro
plate reader.
Caspase 3 activity was determined in cell lysates by using a
fluorimetric assay kit (Caspase-3 Fluorescence kit; Cayman Chemical
Company, Ann Arbor, MI, USA) according to the manufacturer’s instruc-
tions. Plates were read in the fluorescence reader by using 485-nm exc
and 535-nm em filters.
Measurement of intracellular ROS
Intracellular levels of ROS were measured using the fluorescent dye
precursor dihydrorhodamine (DHR) 123 [47], which is converted to
fluorescent rhodamine 123 upon reaction with ROS. Cells were seeded
in 96-well plates, allowed to settle overnight, and loaded in the dark at
room temperature for 30 min. with DHR-123 (30 lM) in a loading
buffer consisting of (mM) 10 Hepes, 140 NaCl, 10 glucose, 1 MgCl2,
2 CaCl2 and 5 KCl, pH 7.4. Cells were then washed with loading buffer
and examined in the fluorescence microplate reader, by using 485-nm
exc and 530-nm em filters. Data of ROS production were expressed as
fluorescence arbitrary units.
Measurements of free cytosolic Ca2+
Variations of free cytosolic Ca2+ were evaluated as described in Ranzato
et al. [9] Briefly, cells were plated on glass-base dishes (Iwaki Glass
Inc., Tokyo, Japan), loaded with the fluorescent Ca2+ probe fluo 3-AM
(20 lM) in the above loading buffer, washed and examined by confocal
time-lapse analysis using a Zeiss LSM 510 confocal system (Carl Zeiss,
Oberkochen, Germany) (exc 488 nm, em 505–550 nm). Cells were
observed through a 209 Plan-Neofluar Zeiss objective (0.5 NA). The
fluorescence of individual cells was recorded using the ROI tool of the
Zeiss LSM 510 2.01 software. Fluo 3 calibration was achieved by the
equation [48]:
Ca2þ ¼ K dðF  FminÞðFmax  F Þ ;
where Kd = 400 nmoles/l. Fmax and Fmin are maximum and minimum
fluorescence intensities obtained by fluo 3 calibration after cell exposure
to 500 lM A23187 for a few minutes, followed by addition of 20 mM
EDTA.
Western immunoblotting
Western blot was carried out as described in Ranzato et al. [9].
Amounts of 100 lg protein from cell lysates were subjected to SDS-
PAGE (12% gel), blotted to nitrocellulose membrane, probed with a pri-
mary monoclonal antibody against the Cav3.2 calcium channel (clone
S55-10, cat. no. 13704, Cayman Chemicals, dilution 1:400), incubated
with horseradish peroxidase-conjugated secondary antibody (Bethyl
Laboratories, Montgomery, TX, USA; dilution 1:1000), developed using
an ECL kit (Millipore, Billerica, MA, USA), acquired by ChemiDoc XRS
(Bio-Rad Laboratories, Hercules, CA, USA) and digitized with the Quan-
tity One Imaging system (Bio-Rad). Equal loading were confirmed with
anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Quantitative reverse transcriptase PCR
(qRT-PCR) and RNA interference (siRNA)
RNA was extracted and cDNA was generated using the Cells-to-CTTM Kit
(Ambion, Foster City, CA, USA). After this, qRT-PCR was performed
using Power Sybr Green Mastermix (Ambion), and a CFX384 Real-Time
PCR Detection System (Bio-Rad Laboratories). Gene expression was








REN cells were transfected with siRNA oligonucleotides (5 lM), or with
equimolar scramble siRNA, by using the N-ter Nanoparticle siRNA
Transfection System. We used commercial siRNA specific to the human
CACNA1H gene, which encodes for the Cav3.2 protein. The sequences
consisted of 5′-CUGACUAAUGCUCUGGAGA (sense) and 5′-UCUCCA-
GAGCAUUAGUCAG (antisense). Scramble siRNA was obtained using
commercial non-targeting siRNA (MISSION siRNA Universal Negative
Control). Cells were harvested at 24, 48 and 72 hrs after transfection
and used for Western blot and other experiments.
Immunohistochemical analysis
A total of eight cases of MMe and two controls were selected from the
archival pathology files of the Pathology Unit of the Regional Hospital
of Mestre-Venice, Italy. All diagnoses of mesothelioma were based on
WHO criteria [49] and confirmed in all instances by clinical, morpholog-
ical and immunohistochemical data. The tissue samples consisted in
videothoracoscopy biopsy or surgical specimens, fixed in neutral
formalin and embedded in paraffin.
Cav3.2 immunostaining was performed on 3 lm-thick paraffin
sections. Slides were deparaffinized according to established proce-
dures, subjected to citric acid antigen retrieval followed by incubation in
3% hydrogen peroxide in PBS to inhibit endogenous peroxidase activity.
Subsequently, pleural sections were blocked for 1 hr at 37°C in PBS
blocking buffer (10% normal goat serum) to inhibit non-specific anti-
body binding. To identify Cav3.2, sections were incubated at 37°C with
the above mentioned mouse monoclonal antibody (Cayman), diluted
1:150 in PBS blocking buffer. After washing, slides were processed
using the IHC Detection Set (Millipore). Briefly, slides were covered with
a biotinylated secondary antimouse antibody and incubated for 1 hr at
37°C, washed and incubated with streptavidin-alkaline phosphatase
complex. Thereafter, labelling was visualized by Fast Red application
and slides were counterstained with hematoxylin. Images were acquired
using an Axiovert Zeiss microscope (Zeiss).
The intensity of immunohistochemical staining was analysed using
Scion Image software (Scion Corp., Frederick, MD, USA). Briefly, digital
micrographs of immunohistochemistry slides were imported from
microscope-mounted digital imaging system as a Scion Image file for
analysis of staining intensity. Representative regions of interest were
then selected from within pleura regions. In addition, a region of inter-
est in an unstained area was selected and measured as background.
Thus, staining intensity was measured, normalized against background
and expressed as mean ± SD of optical density.
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Statistics
Data were analysed by ANOVA using the Instat Software package
(GraphPad Software, Inc., San Diego, CA, USA ). Values of IC50 and their
95% confidence intervals (95% CI) were determined using a downhill sig-
moidal dose–response curve developed by CSIRO, Australia [50]:
y ¼ T
1þ expðSðlogD  log IC50ÞÞ ;
where T = top, S = Hill’s slope (negative for a downhill curve),
D = EGCG concentration in lmoles/l. Statistical comparisons between
IC50 values were based on overlapping or non-overlapping 95%
confidence intervals.
Results
EGCG induces MMe cell death and apoptosis
The first step of this research was the evaluation of EGCG cytotoxicity
to various MMe cell lines, in comparison to normal mesothelial cells,
by using the calcein-AM endpoint. These analyses showed signifi-
cantly lower IC50 values for MMe with respect to non-neoplastic
mesothelial cells (Table 1), indicating a clear selective cytotoxicity of
EGCG to tumour cells.
The underlying mechanism of toxicity was then explored by using
REN cells, whose tumourigenicity has been assessed on mouse
models [42]. The LDH and caspase 3 assays were used to differenti-
ate mechanisms of necrosis from apoptosis. The rate of LDH
release showed a non-linear, dose-dependent increase in the range
5–500 lM EGCG (Fig. 1A). The activity of caspase 3, representing
an index of apoptosis, showed an increase at 5 and 10 lM EGCG,
and then a progressive decline at higher concentrations, down to
levels below control values (Fig. 1B). Hence, these data indicate
that in EGCG-exposed cells, there is a prevalence of apoptosis at
lower concentrations and a progressive prevalence of necrosis at
higher doses.
EGCG-dependent toxicity to MMe cells is
because of the extracellular production of H2O2
It is already known that EGCG induces H2O2 production in cell cul-
tures [35, 51, 52]. By using an H2O2 assay, we found that EGCG is
able to induce the release of this ROS in REN cultures, and that a
lower but significant production is also elicited in the absence of cells
(Fig. 2A). We then evaluated whether the addition of exogenous cata-
lase (CAT), which scavenges H2O2, may reduce EGCG cytotoxicity.
Cell viability tests based on calcein (Fig. 2B) and DNA assays
(Fig. 2C) consistently showed that CAT is able to block the cytotoxic-
ity of EGCG to REN cells. Moreover, CAT almost abolished the release
of LDH from cells exposed to increasing doses of EGCG (Fig. 3A),
and also abolished the activation of caspase 3 activity at low EGCG
doses and its scaling down at higher doses (Fig. 3B). Taken together,
these data indicate that the cytotoxicity of EGCG to MMe cells is
largely dependent on the extracellular production of H2O2.
Table 1 Cytotoxicity of EGCG to MMe and non-neoplastic
mesothelial cells, measured by the calcein-AM endpoint at 24 hrs







HMC h-TERT 309 267–359
Values of IC50 and 95% confidence intervals (95% CI) were derived
from three separate experiments, each with eight replicates (see
Methods for further details). Non-overlapping 95% CI indicate signifi-
cant differences.
Fig. 1 (A) Lactate dehydrogenase (LDH) release in the supernatant of
REN cells after exposure to increasing EGCG concentrations for 6 hrs.
Data are means ± SD derived from 5 to 9 independent treatments, and
expressed as optical densities at 492 nm (see Methods). *P < 0.01
with respect to control according to the Dunnett’s test. (B) Caspase 3
activity measured in REN cells exposed to EGCG as above. Data are
means ± SD derived from 10 independent treatments, and expressed as
fluorescence arbitrary units (see Methods). Different letters on bars
indicate significant differences according to the Tukey’s test (P < 0.01).
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EGCG cytotoxicity involves free cytosolic Ca2+
dysregulation
Mechanisms of cell toxicity, particularly those involving oxidative
stress, are strictly linked to a deregulation of cytosolic free calcium
concentration ([Ca2+]i). In addition, EGCG is known to disrupt cell
Ca2+ homeostasis [53]. Hence, we assessed cell Ca2+ variations
induced by EGCG in MMe cells, by using time-lapse confocal microscopy
imaging of REN cells loaded with the fluorescent Ca2+ probe fluo 3.
Confocal imaging showed that EGCG induces a progressive and
sustained [Ca2+]i rise, indicating Ca
2+ homeostasis disruption
(Fig. 4A). Such an effect was almost completely prevented by addi-
tion to the cell medium of CAT or the sulfhydryl-preserving agent
dithiothreitol (DTT) (Fig. 4A).
To disclose the mechanism of this Ca2+ disorder, we evaluated
the possible role of calcium channels. A growing body of evidence
suggests that T-type Ca2+ channels are abnormally expressed in
cancerous cells [54]. We therefore evaluated the effect of typical
T-type channel inhibitors, viz. mibefradil [55] and Ni2+ [56], on the
Ca2+ rise induced by EGCG. Confocal imaging showed that REN cell
preincubations with mibefradil or Ni2+, used in the form of NiCl2,
were able to prevent Ca2+ homeostasis loss caused by EGCG
(Fig. 4A). Cell incubation with mibefradil, NiCl2 or the mibefradil’s
vehicle DMSO, each used alone, were ineffective on Ca2+ (not
shown). In addition, we also measured EGCG cytotoxicity to REN
cells in the presence or absence of 5 lM mibefradil, finding that
the Ca2+ channel blocker induces a significant shift of the EGCG
IC50, from 95 lM (95% CI: 84–106) to 586 lM (95% CI: 516–
664).
EGCG induces ROS increase within MMe cells
Given that cell Ca2+ alteration and excessive ROS production are
known to cooperatively promote cell death processes, we also
explored the development of ROS within MMe cells. In these exper-
iments, intracellular ROS production was evaluated by recording
the fluorescence of DHR 123-loaded REN cells in a microplate
reader. Similar to what was observed with Ca2+, EGCG induced a
sustained rise in ROS production, which was abolished by exoge-
nous CAT, and, most intriguingly, also by cell loading with the
cell-permeant Ca2+ chelator BAPTA-AM or by cell preincubation
with mibefradil (Fig. 4B).
EGCG acts differently on [Ca2+]i and ROS in MMe
and mesothelium
The cytotoxicity data reported in Table 1 indicate that MMe cells are
more sensitive to EGCG than normal mesothelial cells. Moreover, we
Fig. 2 (A) Production of H2O2 in DMEM medium after 1 hr incubation with increasing EGCG concentrations, in the presence or absence of REN
cells. Data are means ± SD (n = 3) of H2O2 concentrations determined as described in the Methods. All groups are significantly different with
respect to their control (P < 0.01, Dunnett’s test). (B) Determination of REN cell viability in response to increasing EGCG, in the presence or
absence of exogenous CAT (500 units/ml). Data are extrapolated from the calcein-AM viability index after exposure of cells to EGCG for 24 hrs, and
are expressed as means ± SD of two independent experiments, each with eight replicates. *P < 0.01 with respect to control according to the Dun-
nett’s test. (C) Viable cell counts performed through microplate fluorometric DNA assays on REN cells, showing dose-response relations to increas-
ing EGCG concentrations in the presence or absence of 500 units/ml CAT. The fluorescent signal was read after incubation with Hoechst 33258 (see
Methods). Data are expressed as means ± SD (n = 8 independent samples) of the estimated numbers of cells. The mean of control without CAT
has been set to 100%. *P < 0.01 with respect to control according to the Dunnett’s test.
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have also shown that EGCG acts by inducing loss of Ca2+ homeosta-
sis and increased ROS production. We therefore compared the effects
of EGCG on [Ca2+]i and ROS in REN and mesothelial cells, by using
confocal imaging and fluorescence plate reader data, recorded as
above after 45 min. of EGCG incubation. These experiments
confirmed that EGCG induces a significant increase of [Ca2+]i and
ROS in REN cells, whereas in contrast in mesothelial cells the
variation of [Ca2+]i was barely significant, and the ROS increase was
significantly lower than in REN cells (Table 2).
Direct cell exposure to H2O2 acts similarly to
EGCG on [Ca2+]i and ROS
As the use of exogenous CAT indicates an involvement of extra-
cellular H2O2 in EGCG cytotoxicity, we ran a series of experi-
ments by directly exposing REN cells to 20 lM H2O2 for 45 min.
Confocal imaging revealed that H2O2 induced a sustained [Ca
2+]i
rise, which was abolished by addition of DTT or mibefradil. Also,
microplate fluorescence data revealed an increase of intracellular
ROS production, which was partially but significantly prevented
by DTT or mibefradil (Table 3).
Cav3.2 silencing abolishes EGCG toxicity
on MMe cells
The above data suggest a role for T-type channels in mediating
EGCG effects on MMe cells. We therefore targeted these channels
by siRNA-mediated knock-down of the CACNA1H gene, encoding for
the Cav3.2 a1H protein. Such an isoform was chosen because it is
known to mediate the redox regulation of neuronal T-type channels
[57].
Quantitative PCR (qRT-PCR) and Western blot analyses
showed, respectively, that the Cav3.2 gene and protein are both
expressed at significant levels in the REN cell line, whereas their
expression is barely detectable in mesothelial cells (Fig. 5A).
Moreover, cell transfection with Cav3.2 siRNA in REN cells
resulted in a lack of Cav3.2 expression, whereas cells transfected
with scramble siRNA showed an expression level similar to
controls (Fig. 5B).
The effect of RNA interference on EGCG cytotoxicity resulted in a
progressive upward shift of the IC50 derived by NRU after 24, 48 or
72 hrs siRNA, with respect to cells subjected to scramble siRNA
(Fig. 5C and D). In addition, we found that Cav3.2 siRNA prevented,
almost completely, the [Ca2+]i rise induced by EGCG, which was
instead observable after scramble siRNA (Fig. 6A). Most importantly,
we also showed that Cav3.2 siRNA was able to prevent the EGCG-
induced rise in intracellular ROS, which also in this case was not
affected by scramble siRNA (Fig. 6A). In agreement with these
results, Cav3.2 siRNA prevented almost completely the release of
LDH, and abolished the pattern of caspase 3 activation/inactivation
induced by EGCG (Fig. 6B).
Cav3.2 is differently expressed in normal pleura
and malignant pleural mesothelioma
The in vivo expression of Cav3.2 was analysed using immunohisto-
chemistry in MMe patients with >5 years of follow-up. Paraffin-
embedded, histological materials were collected from eight MMe
patients, including two sarcomatous, four epithelioid and two
biphasic types, and from two normal controls. Immunoreactive
staining was measured as described in the Methods, and a signifi-
cantly more intense signal was observed in all kinds of MMe with
respect to controls (Fig. 7A). Quantitative measurements of histo-
chemical staining confirmed higher Cav3.2 expression in MMe
tissue (Fig. 7B), consistent with the in vitro finding of Cav3.2
expression in REN cells, pointed out by the above mentioned
Western blot and qRT-PCR data.
Fig. 3 (A) Lactate dehydrogenase (LDH) release in the supernatant of
REN cells after 24 hrs exposures to different EGCG concentrations in
the presence or absence of CAT (500 units/ml). Data are means ± SD
(n = 6 independent replicates) expressed as absorbances at 492 nm
(see Methods). (B) Caspase 3 activity measured in REN cells exposed
for 6 hrs to EGCG in the presence or absence of 500 units/ml CAT.
Data are means ± SD derived from 3 to 5 (without CAT) or 8 to 11
(with CAT) independent treatments, and expressed as fluorescence arbi-
trary units (see Methods). For each series, different letters on bars indi-
cate significant differences according to the Tukey’s test (P < 0.01).
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Discussion
In this study, we have found that EGCG exerts an MMe antitumour
effect, as shown by its selective in vitro cytotoxicity on MMe cells,
with respect to normal mesothelial ones. The LDH and caspase 3
assays confirmed the anti-proliferative effect of EGCG, showing the
induction of both necrotic and apoptotic effects. However, the induc-
tion of necrosis was strictly dose-dependent, whereas caspase 3 acti-
vation was prevalent over necrosis at lower doses, but showed a
decreasing trend down to values below controls for higher EGCG
doses. The results of subsequent experiments provided a rationale for
explaining such a divergent trend, as will be discussed below.
The detection of H2O2 production in cell culture medium provided
a first hint for the mechanism of EGCG-induced cell damage. Release
of H2O2 was detected even in the absence of cells, but occurred in
higher amounts when cells were present. This confirms previous
reports that catechins, although being generally known as
antioxidants, may also induce oxidative stress and specifically pro-
voke the release of H2O2 in the presence of transition metals [58–60].
Catechin pro-oxidant effects are known to be responsible for the
induction of apoptosis, and are supposed to have a role in cancer pre-
vention [61–64]. Such a view was fully confirmed by our results,
showing that exogenous catalase can block or strongly reduce the
anti-proliferative effects of EGCG, and moreover that it hampers the
induction of cell apoptosis and necrosis, as revealed by LDH and
caspase 3 assays. It is worth noting that catalase blocked caspase 3
activation at lower EGCG doses, as well as the decrease of the enzyme
activity observed at higher doses, thus showing that both effects
depend on extracellular H2O2 production.
Fig. 4 (A) Intracellular Ca2+ variations recorded each minute for a period of 45 min. in individual REN cells, by using confocal imaging (see Meth-
ods). Upper panel. Exposure to 100 lM EGCG induces a sustained rise in [Ca2+]i that is indicative of Ca
2+ homeostasis disruption. External additions
of DTT (2.5 mM) or CAT (500 units/ml) abolish the effect of EGCG (P < 0.001, Tukey’s test carried out on 45-min. data). Lower panel. Pre-incuba-
tion with the Ca2+ channel blockers mibefradil (5 lM) or Ni2+ (30 lM NiCl2) significantly prevent the [Ca
2+]i rise induced by 100 lM EGCG
(P < 0.001, as above). Data are means ± SD of [Ca2+]i values recorded in different cells from three different experiments. Number of cells: 32 (con-
trol), 37 (EGCG), 33 (EGCG + DTT), 40 (EGCG + CAT), 26 (EGCG + mibefradil), 40 (EGCG + NiCl2). (B) ROS production in DHR 123-loaded REN
cells growing in 96-well plates, recorded each 2 min. for a period of 46 min. in a fluorescence plate reader (see Methods). Upper panel: Exposure
to 100 lM EGCG induces an increase in ROS production that is abolished by cell loading with the membrane-permeant Ca2+ chelator BAPTA-AM, or
by external addition of 500 units/ml CAT (P < 0.001, as above). Lower panel: Pre-incubation with the Ca2+ channel blocker mibefradil (5 lM) pre-
vents the rise in ROS production induced by 100 lM EGCG (P < 0.001, as above). Inset: Fluorescence values recorded at 45 min. in control cells
(ctrl), or in cells incubated with EGCG alone (e), EGCG/mibefradil (E + m) and mibefradil alone (m) (*P < 0.001, Tukey’s test). Data are
means ± SD of rhodamine 123 fluorescence expressed in arbitrary units; n = 16 microplate wells from two different experiments.
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The blocking of injurious effects of EGCG by exogenous catalase
is clear evidence that H2O2 acts extracellularly. Hence, we had to
search for mechanisms able to transduce H2O2 effects into cell death
pathways. Calcium ions are central to multiple signal transduction,
but anomalous elevations of [Ca2+]i can switch from physiological to
cell death signal, e.g. via the disruption of mitochondrial Ca2+ equilib-
rium. Moreover, excess intracellular ROS is frequently intertwined
with cytosolic Ca2+ increase, thus sharing a main role in driving cells
towards apoptosis or necrosis. For instance, Ca2+ overload and oxida-
tive damage from ROS production induce mPTP opening and
mitochondrial dysfunction [63, 64].
Our data indicate that both [Ca2+]i and ROS elevations occur in
MMe cells experiencing EGCG treatments. In addition, we have also
found that these events occur with higher intensity in MMe cells
with respect to mesothelium, hence suggesting their involvement in
the selective cytotoxicity of EGCG to MMe cells. Data of confocal
calcium imaging showed that the EGCG-dependent [Ca2+]i rise in
MMe cells derives from extracellular pro-oxidant effects, as shown
by catalase and DTT inhibition. In addition, the inhibitory action of
mibefradil and Ni2+ suggested that plasma membrane Ca2+
channels are involved.
Fig. 5 (A) Expression of the Cav3.2 calcium channel gene and Cav3.2
protein in REN and mesothelial cells. Left panel: the mRNA quantity of
Cav3.2 was determined by qRT-PCR (see Methods) and is represented
as mean relative expression ± SD (n = 3, *P < 0.001, t-test). Right
panel: Western immunoblot analysis of cell lysates showing quite
detectable expression of Cav3.2 peptide in REN cells and barely detect-
able expression in mesothelium. (B) Western immunoblot analysis of
REN cell lysates showing Cav3.2 down-regulation by RNA interference
(siRNA). REN cells were transfected or not (none) with 5 lM negative
control siRNA (), or specific Cav3.2 siRNA (+), with a 24-hr interval.
(C) Dose-response curves derived from the NRU endpoint, showing a
significant reduction of EGCG cytotoxicity to REN cells after 72 hrs
Cav3.2 siRNA, with respect to scramble siRNA, as shown by rightward
IC50 shift (P < 0.05). Data are means ± SD percent cell viabilities
obtained from eight replicates. Downhill logistic regression lines, IC50
values (vertical lines) and 95% CI (horizontal bars) are shown. (D) Vari-
ation of EGCG IC50 on REN cells, after 24, 48 or 72 hrs Cav3.2 siRNA,
or 24 hrs scramble siRNA. Data are means IC50 obtained from three
independent experiments ±95% CI. *P < 0.05, **P < 0.01, with respect
to scramble siRNA, according to the Dunnett’s test.
Table 2 Effect of EGCG on [Ca
2+]i and ROS production in REN and
mesothelial cells
Cell type Treatment [Ca2+]i (nM) ROS






771 ± 507b (21) 21.9 ± 3.2b (25)
Mesothelium control 57 ± 12a (9) 5.9 ± 1.1a (10)
Mesothelium 100 lM
EGCG
169 ± 77a (24) 12.4 ± 3.2c (16)
Data are means ± SD of [Ca2+]i expressed as nM, and of ROS pro-
duction expressed as rhodamine 123 fluorescence in arbitrary units,
recorded after 45 min. of treatment (no. of cells or wells are given in
parentheses; see Methods for further details). In each column, differ-
ent superscript letters indicate significant differences according to the
Tukey’s test (P < 0.01).
Table 3 Effects of H2O2 on [Ca
2+]i and ROS in REN cells, and
suppressive actions of DTT and mibefradil
Treatment [Ca2+]i (nM) ROS
Control 80 ± 35a (n = 32) 7.2 ± 0.57a (n = 16)
20 lM H2O2 1102 ± 713
b (25) 21.2 ± 1.8b (16)
20 lM H2O2 +
5 lM mibefradil
184 ± 45a (31) 16.8 ± 1.6c (16)
20 lM H2O2 +
2.5 mM DTT
90 ± 66a (25) 11.2 ± 3.0d (16)
Data and statistics as in Table 2.
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The data of DHR 123 fluorescence showed that also ROS pro-
duction within cells depends on extracellular H2O2 induced by
EGCG. Most interestingly, this process seems to be mediated by
[Ca2+]i through the opening of plasma membrane Ca
2+ channels, as
shown by prevention of ROS increase in cells preloaded with
BAPTA-AM or pre-incubated with mibefradil. Hence, the ROS
production triggered by EGCG appeared as a downstream effect of
[Ca2+]i rise, a pathway that closely resembles what has been
observed in EGCG-exposed rat hippocampal neurons [53]. Further
evidence supporting this mechanism was the observation of DTT-
and mibefradil-sensitive [Ca2+]i rise and ROS increase in REN cells
directly exposed to H2O2.
It is known that oxidative processes can lead to Ca2+ leakage, by
acting on either plasma membrane or intracellular Ca2+ channels [65,
66]. In electrically non-excitable cells, the regulatory mechanism
mediating Ca2+ entry is unclear, but in general, these cells do not
express voltage-gated Ca2+ channels. However, it has been found that
these channels are overexpressed by different tumour cells, and it
has also been suggested that they promote the proliferation of malig-
nant cells through the regulation of Ca2+ entry mechanisms [54, 67,
68]. Various hepatocarcinoma cell lines have been found to express
one or more alpha-1, T-type Ca2+ channel subunits, although obvious
T-type currents have been detected only in one of these cell types
[68]. According to the supposed role of T-type channels in tumour
cell growth, the possible anti-cancer use of T-type channel blockers
has been investigated [69].
We have investigated the role of T-type channels as the transduc-
ing element between the EGCG-induced extracellular H2O2 release
and the intracellular injurious effects observed in MMe cells. The first
evidence of this mechanism was provided by the preventive action of
mibefradil and Ni2+ on Ca2+ homeostasis disruption by EGCG. Hence,
to achieve a more direct confirmation, we targeted the Cav3.2 isoform
that is considered a major substrate for redox regulatory mecha-
nisms. The higher expression of this channel in MMe cells, as
compared to normal mesothelium, provided a first rationale for the
selective toxicity mechanism of EGCG to MMe cells. However, defini-
Fig. 6 (A) Upper panel: Measurements of [Ca2+]i by confocal imaging in fluo 3-loaded REN cells exposed or not to 100 lM EGCG for 45 min. In
scramble siRNA-treated cells, EGCG induces a [Ca2+]i rise similar to the one observed in unmanipulated cells, whereas Cav3.2 siRNA significantly
reduces such an effect. Data are means ± SD of [Ca2+]i values recorded in single cells from two different experiments. Number of cells: 26 (control/
scramble siRNA), 31 (EGCG/scramble siRNA), 28 (control/Cav3.2 siRNA), 63 (EGCG/Cav3.2 siRNA). Lower panel: ROS production in DHR 123-loaded
REN cells growing in 96-well plates, evaluated by rhodamine 123 after 45-min incubations with or without 100 lM EGCG. Pre-treatment with Cav3.2
siRNA for 24 hrs abolishes the ROS increase induced by EGCG, whereas scramble siRNA does not prevent it. The results are representative of two
independent experiments. Data are mean fuorescence values ± SD, n = 20. Different letters on bars indicate significant differences according to the
Tukey’s test (P < 0.01). (B) Upper panel: LDH release in the supernatant of REN cells pretreated with Cav3.2 siRNA, or with scramble siRNA, and
then exposed to increasing EGCG concentrations for 6 hrs. Data are means ± SD derived from 6 to 8 independent treatments, and expressed as
optical densities at 492 nm (see Methods). Lower panel: Caspase 3 activity measured in REN cells pretreated with siRNA and exposed to EGCG as
above. Data are means ± SD derived from 10 to 20 independent treatments, and expressed as fluorescence arbitrary units (see Methods).
*P < 0.01 with respect to control according to the Dunnett’s test.
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tive evidence derived from the ability of Cav3.2 siRNA to inhibit all the
observed effects of EGCG, from cytotoxicity endpoints to intracellular
[Ca2+]i and ROS increases. These results are quite consistent with the
strong reduction of EGCG cytotoxicity observed in MMe cells
pre-incubated with mibefradil.
Consistent with the above findings, Cav3.2 siRNA was also able to
lower LDH release and drastically modify the pattern of caspase 3
activation by EGCG. Data of caspase 3 under Cav3.2 siRNA are similar
to those observed in the presence of CAT, as they show a lack of
caspase 3 activation at low EGCG concentrations, but also of the scal-
ing down of caspase 3 activity at higher doses of catechin. Hence, by
putting all data together, we can suggest that low EGCG doses
(<50 lM) would lead to moderate intracellular Ca2+ rise and ROS
production, thus inducing caspase 3 activation followed by apoptosis.
Conversely, at higher EGCG doses, severe injury following strong
Ca2+ alteration and ROS production would upset cell functioning,
thereby leading to massive cell necrosis and the disappearance of
caspase 3 activity.
In conclusion, we have reconstructed a selective mechanism of
EGCG toxicity to MMe cells, based on the expression in these cells of
T-type Ca2+ channels (Fig. 8). The mechanism can be summarized as
follows:
(1) EGCG induces H2O2 release at the outside of cells;
(2) H2O2 acts by inducing T-channel opening at the plasma
membrane;
(3) Ca2+ leakage into the cytosol causes [Ca2+]i rise and
triggers ROS production;
(4) Ca2+ and ROS cooperate in inducing either apoptosis or
necrosis, depending on damage.
Hence, our data have demonstrated for the first time that
EGCG can selectively inhibit the proliferation of MMe cells and
moreover that T-type Ca2+ channels are involved in the mecha-
nism of action of the green tea polyphenol. In addition, we have
also provided evidence that T channels are expressed in the can-
cerous tissue of MMe patients at higher levels than in normal
pleura. On the basis of these data, we are proposing T channels
as a novel potential therapeutic target for this chemoresistant
tumour, a poor-prognosis disease that still lacks an efficient
therapy.
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Fig. 7 (A) Immunohistochemical staining of Cav3.2 in normal pleura and
in three types of MMe tissue (sarcomatous, epithelioid and biphasic).
Immunoreactivity is scarcely detected in normal pleura, but it is clearly
and differentially expressed (bright pink) in tumours. Bar = 30 lm. (B)
Quantification of Cav3.2 immunoreaction obtained by digital imaging of
stained slides (see Methods). Data are expressed as means ± SD of
optical densities (n = 75–155 different microscope fields). *P < 0.01.
Fig. 8 Diagram depicting the mechanism of action of EGCG on MMe
cells, as characterized in this study (see text for further explanation).
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